Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial
Given the high prevalence of uncontrolled gout in KT recipients, proper SU management is of particular importance. Additionally, intensive urate-lowering with pegloticase may have clinical and QOL benefits.
Authors
- K. Obermeyer
- Brad A. Marder (ORCID: https://orcid.org/0000-0002-3204-082X)
- Abdul Abdellatif
- John D. Scandling (ORCID: https://orcid.org/0000-0001-6493-3318)
- Zana Vranic (ORCID: https://orcid.org/0009-0001-2358-434X)
- Lin Zhao (ORCID: https://orcid.org/0000-0003-0073-2204)
Institutions
- Amgen (United States) (US)
- Baylor College of Medicine (US)
- Horizon Therapeutics (United States) (US)
- Stanford Medicine (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1516146
- Citations
- 3
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 4.29
Funders
- Amgen